98027-36-2

Usage

Uses

Used in Pharmaceutical Industry:
2-HYDROXY-3-AMINO-5-CHLOROPYRIDINE is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activities. Its unique structure allows for the development of new drugs with improved therapeutic effects and reduced side effects.
Used in Agrochemical Industry:
In the agrochemical industry, 2-HYDROXY-3-AMINO-5-CHLOROPYRIDINE is utilized as a building block for the creation of novel agrochemicals, such as pesticides and herbicides, that can effectively control pests and diseases in agriculture while minimizing environmental impact.
Used in Dye and Pigment Industry:
2-HYDROXY-3-AMINO-5-CHLOROPYRIDINE is employed as a precursor in the production of dyes and pigments, offering a wide range of color options and improved properties, such as enhanced colorfastness and stability, for various applications in textiles, plastics, and other industries.
Used in Antifungal and Antimicrobial Applications:
Due to its inherent antifungal and antimicrobial properties, 2-HYDROXY-3-AMINO-5-CHLOROPYRIDINE is used as an active ingredient in various formulations for controlling fungal and bacterial infections in medical, agricultural, and industrial settings. Its broad-spectrum activity makes it a valuable asset in the development of new antimicrobial agents.
Used in Research and Development:
2-HYDROXY-3-AMINO-5-CHLOROPYRIDINE is a subject of interest for further research in pharmaceutical and agricultural applications, as its unique structure and properties hold potential for the discovery of new compounds with improved efficacy and selectivity. Researchers are exploring its use in the development of targeted therapies, as well as its potential to enhance the performance of existing products.

InChI:InChI=1/C5H5ClN2O/c6-3-1-4(7)5(9)8-2-3/h1-2H,7H2,(H,8,9)

Upstream product

• 21427-61-2 5-chloro-3-nitropyridin-2-ol 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND

Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

3-(BIARYLOXY) PROPIONIC ACID DERIVATIVE

A compound of the general formula (I): [wherein, R1 represents a halogen atom, or the like, R2 represents a hydrogen atom, or the like, R3 and R4, each independently, represent a hydrogen atom, a C1-4

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane (CP-810,123), a novel α7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: Synthesis, SAR development, and in vivo efficacy in cognition models

A novel α7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4- diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that α7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia. 2009 American Chemical Society.

AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS

The present invention relates to a7 nicotinic receptor agonists of formula (la) or (lb) as described herein and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal an a7 nicotinic receptor agonist of formula (la) or (lb). It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant a7nicotinic receptor agonist of formula (la) or (lb).